In a move to enhance patient safety and abuse, UK pharmacies should now apply stricter tests before distributing weight loss drugs such as Wegovy and Mounjaro. These measures are aimed at preventing people who are already healthy weight or have a history of eating disorders from access to these high -risk medicines without proper medical supervision.
Credit Picture: Alones/Shutterstock.com
According to the new regulations, online pharmacies will no longer be able to prescribe these medicines based exclusively on questionnaires online or submitted photos. Instead, patients must undergo personal or video clips to verify the Body Mass Index (BMI) and provide supportive medical files or information from their General physician (GP).
The General Pharmaceutical Council (GPHC) emphasized that non -compliance with these enhanced guidelines could lead to enforcement actions, including inspections, fitness research and compulsory improvement. These measures come amid concerns about unsafe prescription practices and potential offer issues, with reports that some e -pharmacies had set quotas for editing per hour.
“We know that web pharmacy services can provide a valuable service, but through our inspections and research, we have seen too many cases of drugs to be provided inappropriate online and endanger people.”
Duncan Rudkin, CEO of GPHC.
Weight loss drugs, including semiaglitis (Wegovy) and Tipaepatide (Mounjaro), were initially developed to help patients with type 2 diabetes manage blood sugar levels. However, their increasing use as a weight loss aid has led to global deficiencies and increasing fake products. Given their classification as high -risk drugs, new guarantees will help ensure their proper and safe use.
These drugs, which work by imitating bowel hormones that regulate hunger and metabolism, have shown a promise beyond weight management. Recent studies show that they can significantly improve heart health by reducing the risks of heart attacks, strokes, heart failure and high blood pressure.
With these new regulations, prescriptionists should also “actively” share information with a patient’s GP about the drugs distributed. This step is expected to improve transparency and ensure a comprehensive approach to patient care.
